Particle deposition in the respiratory tract

Finlay, Warren H.

doi:10.1016/b978-0-08-102749-3.00007-5

Cited by 1 publication

(4 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…From the trachea to the alveoli, there are approximately 23 diverging and asymmetric divisions. As inhaled air travels along the complex respiratory tract, many particles in the airstream are removed by inertial impaction at airway bifurcations [5]. At the end of inhalation, the air flow is reversed.…”

Section: Depositing In the Target Region Within The Lungmentioning

confidence: 99%

“…Inhaled particles with smaller size or lower density have limited time to settle to their target sites unless a breath hold maneuver is incorporated at the end of the inhalation. Particles still air-borne at the end of inhalation are then driven out of the lung and some of them land on the respiratory tract walls along the way [5]. Therefore, while employing inhaled air to deliver drugs to the lung is a sensible approach, targeting exclusively the trachea-bronchial or the alveolar regions is extremely difficult [5].…”

Section: Depositing In the Target Region Within The Lungmentioning

confidence: 99%

“…Particles still air-borne at the end of inhalation are then driven out of the lung and some of them land on the respiratory tract walls along the way [5]. Therefore, while employing inhaled air to deliver drugs to the lung is a sensible approach, targeting exclusively the trachea-bronchial or the alveolar regions is extremely difficult [5]. Utilizing more rapid inhalations and larger aerosol particles (e.g., 6 µm) will increase trachea-bronchial deposition over alveolar deposition, although at the expense of greater deposition in the oropharynx.…”

Section: Depositing In the Target Region Within The Lungmentioning

confidence: 99%

“…For successful delivery to the lung, the inhaled aerosol must avoid deposition in the oropharyngeal region. As aerosol droplets or particles are inhaled, their momentum can lead to deviation from a bending air flow path, resulting in aerosol impaction on the surfaces of the mouth or throat and a reduction in the dose to the lung [4,5]. Aerosol devices delivering particles with smaller aerodynamic diameters, which can be achieved by a combination of lower density or smaller geometric size, can more easily avoid aerosol impaction in the oropharyngeal region.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Strategies to Overcome Biological Barriers Associated with Pulmonary Drug Delivery

et al. 2022

View full text Add to dashboard Cite

While the inhalation route has been used for millennia for pharmacologic effect, the biological barriers to treating lung disease created real challenges for the pharmaceutical industry until sophisticated device and formulation technologies emerged over the past fifty years. There are now several inhaled device technologies that enable delivery of therapeutics at high efficiency to the lung and avoid excessive deposition in the oropharyngeal region. Chemistry and formulation technologies have also emerged to prolong retention of drug at the active site by overcoming degradation and clearance mechanisms, or by reducing the rate of systemic absorption. These technologies have also been utilized to improve tolerability or to facilitate uptake within cells when there are intracellular targets. This paper describes the biological barriers and provides recent examples utilizing formulation technologies or drug chemistry modifications to overcome those barriers.

show abstract

Section: Depositing In the Target Region Within The Lungmentioning

confidence: 99%

Section: Depositing In the Target Region Within The Lungmentioning

confidence: 99%